Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Jaffe

Showing results (501-510 of 579) with videos related to

Pageof 58
Sort By:
Ophthalmology|May 3, 2017
Comparison of Visual Outcomes in Coats' Disease: A 20-Year ExperienceSally S Ong, Edward G Buckley, Brooks W McCuen, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 30, 2011
Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degenerationKang Zhang, Jill J Hopkins, Jeffrey S Heier, et al.
Eye (London, England)|March 25, 2023
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trialSunil S Patel, David R Lally, Jason Hsu, et al.
NEJM Evidence|July 22, 2025
Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2Emily Y Chew, Mark Gillies, Glenn J Jaffe, et al.
Investigative Ophthalmology & Visual Science|August 21, 2020
Risuteganib Protects against Hydroquinone-induced Injury in Human RPE CellsPing Yang, Zixuan Shao, Nicholas A Besley, et al.
Eye (London, England)|May 26, 2023
Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trialSunil S Patel, David R Lally, Jason Hsu, et al.
Retina (Philadelphia, Pa.)|July 16, 2025
IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALSGlenn J Jaffe, Gábor Deák, Kara Gibson, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2013
Aryl hydrocarbon receptor deficiency causes dysregulated cellular matrix metabolism and age-related macular degeneration-like pathologyPeng Hu, Rolf Herrmann, Amanda Bednar, et al.
Ophthalmology|November 27, 2018
Five-Year Follow-up of Nonfibrotic Scars in the Comparison of Age-Related Macular Degeneration Treatments TrialsEbenezer Daniel, Gui-Shuang Ying, Benjamin J Kim, et al.
Ophthalmology|March 8, 2017
Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy: Results of 2 Randomized Phase 3 StudiesRishi P Singh, Robert Lehmann, Joseph Martel, et al.
Pageof 58

Showing results (501-510 of 579) with videos related to

Sort By:
Pageof 58
Ophthalmology|May 3, 2017
Comparison of Visual Outcomes in Coats' Disease: A 20-Year ExperienceSally S Ong, Edward G Buckley, Brooks W McCuen, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 30, 2011
Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degenerationKang Zhang, Jill J Hopkins, Jeffrey S Heier, et al.
Eye (London, England)|March 25, 2023
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trialSunil S Patel, David R Lally, Jason Hsu, et al.
NEJM Evidence|July 22, 2025
Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2Emily Y Chew, Mark Gillies, Glenn J Jaffe, et al.
Investigative Ophthalmology & Visual Science|August 21, 2020
Risuteganib Protects against Hydroquinone-induced Injury in Human RPE CellsPing Yang, Zixuan Shao, Nicholas A Besley, et al.
Eye (London, England)|May 26, 2023
Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trialSunil S Patel, David R Lally, Jason Hsu, et al.
Retina (Philadelphia, Pa.)|July 16, 2025
IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALSGlenn J Jaffe, Gábor Deák, Kara Gibson, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2013
Aryl hydrocarbon receptor deficiency causes dysregulated cellular matrix metabolism and age-related macular degeneration-like pathologyPeng Hu, Rolf Herrmann, Amanda Bednar, et al.
Ophthalmology|November 27, 2018
Five-Year Follow-up of Nonfibrotic Scars in the Comparison of Age-Related Macular Degeneration Treatments TrialsEbenezer Daniel, Gui-Shuang Ying, Benjamin J Kim, et al.
Ophthalmology|March 8, 2017
Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy: Results of 2 Randomized Phase 3 StudiesRishi P Singh, Robert Lehmann, Joseph Martel, et al.
Pageof 58